Biocon Ltd. said Tuesday the FDA issued a complete response letter (CRL) for partner Mylan NV's BLA for MYL-1401H, a proposed biosimilar of Amgen Inc.'s Neulasta (pegfilgrastim), the latest biosimilar version of the long-acting G-CSF drug to hit a regulatory snag.